The agreement with Ayana Pharma is likely to provide Scinai Immunotherapeutics with a steady revenue stream over the next five years, enhancing its financial stability and potentially its stock price. The partnership also positions Scinai as a key player in the drug development and manufacturing sector, which could attract further business and partnerships.